Search Results

CSL Behring, based in King of Prussia, Pennsylvania, is acquiring Vancouver, British Columbia-based Vitaeris. The two companies inked a strategic partnership in 2017 to accelerate the development of Vitaeris’s clazakizumab. At that time, CLS Behring also had an option to acquire Vitaeris, the therapeutic, and the rest of Vitaeris’s assets.

Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB)

CSL Limited and Vitaeris today announced that they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab as a therapeutic option for solid organ transplant rejection.

Anti-Interleukin 6 Monoclonal Antibody for Antibody-Mediated Kidney Transplant Rejection

Incisive Genetics Inc. (“IG”), a biotech company specializing in the research and development of a novel non-viral delivery platform for targeted CRISPR-based gene therapies, announced today the appointment of Kevin Chow, Ph.D. as President.

DUBAI, United Arab Emirates, According to a latest study by Future Market Insights, global needle-free injectors sales are expected to reach US$ 12.3 Bn in 2021, surging at 11.9% CAGR during the forecast period.

Health Canada is advising Canadians that soft-shelled hyperbaric chambers that are promoted online or offered as a service to consumers to treat a variety of medical conditions—including autism, cerebral palsy and migraines—are unlicensed medical devices and may pose serious health risks.

Accelerator Life Science Partners (ALSP), a leading early-stage life science management and venture capital firm, announced today the expansion of its world-class advisory teams with the addition of several renowned leaders in the life science industry.

In its annual R&D briefing to investors today, CSL Limited (ASX:CSL; USOTC:CSLLY) demonstrated how the company is advancing a novel research portfolio across four strategic scientific platforms (Plasma Fractionation, Recombinant Technology, Cell and Gene Therapy, Adjuvanted Cell and Egg-based Vaccines) across six therapeutic areas (Immunology, Hematology, Respiratory

Immune-stimulating Antibody Conjugate (ISAC) Immunotherapy Technology Attracts Seasoned Biotech Business Leader